Navigation Links
Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
Date:5/3/2011

SAN MATEO, Calif., May 3, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced dosing of the first patient in a Phase I clinical trial investigating the use of subcutaneous cenderitide.  The trial is being conducted pursuant to Nile's previously announced collaboration with Medtronic and is the first clinical step towards developing cenderitide as a treatment for the post-acute heart failure space, a strategy which was recently granted Fast Track status by the United States Food and Drug Administration (FDA).

"This clinical trial signals the beginning of a new paradigm in the development of therapies for heart failure patients," said James Young, MD Professor and Executive Dean, Cleveland Clinic Lerner College of Medicine. "Administration of cenderitide on an outpatient basis could change how heart failure patients are treated and has the potential to reduce re-hospitalizations by targeting multiple aspects of the heart failure disease process."

The Phase I clinical trial is a placebo-controlled study designed to evaluate pharmacokinetic and pharmacodynamic actions of cenderitide when administered to chronic heart failure patients as a subcutaneous infusion or as a subcutaneous bolus injection. In the first part of the trial, patients will receive two subcutaneous bolus injections of cenderitide.  In the second part of the trial, patients will receive either a 24 hour continuous infusion of cenderitide or placebo, delivered through Medtronic's subcutaneous pump technology. The primary purpose of the trial is to understand the doses required to achieve pre-determined plasma levels of cenderitide delivered through a subcutaneous infusion pump and the pharmacodynamic activity at these doses.

"This clinical trial is a key first step in our post
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  Decision Resources Group is launching an extension ... to now include ChinaTrack; the new capabilities track the ... interactive dashboard providing detailed brand-level share tracking and analytics. ... level. Other key capabilities of the new ... addition to end-user surveys of healthcare facilities, ChinaTrack data ...
(Date:7/31/2014)... -- Hovione today announced that its API plant ... a pre-approval inspection by the US Food and Drug Administration ... Consumer Safety Officer, Ms. Britanny Terhar , lasted 5 ... and concluded on the 25 th . The inspection confirmed ... of Good Manufacturing Practices (GMP) and no Form 483 observations ...
(Date:7/31/2014)... NEW YORK and VIENNA , ... today at a press conference in New York ... of PD01A, a vaccine against Parkinson,s disease. PD01A is the ... target, to enter clinical testing. The Michael J. ... a $ 1.5 million grant, and presented at the press ...
Breaking Medicine Technology:Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4
... April 21, 2011 iMD Companies (ICBU.PK) is pleased ... Testing Facility (IDTF), Optimum Mobile Imaging LLC, which increases ...  The acquisition was done with cash and restricted stock ... can be found at www.OMIAZ.com .   OMI ...
... MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, ... today the Company,s attendance at the upcoming International Society ... 26 – 29, 2011.  The meeting will be held ... / Palazzo Hotels in Las Vegas, Nevada.   ...
Cached Medicine Technology:iMD Companies, Inc. Acquires OMI LLC and Files Financials for 2010 2iMD Companies, Inc. Acquires OMI LLC and Files Financials for 2010 3MiMedx to Attend International Society for the Advancement of Spine Surgery Annual Meeting 2
(Date:7/31/2014)... 31, 2014 Leelanau Peninsula’s newest winery, ... 2014 at 7788 East Horn Road in Lake Leelanau. Joining ... , Aurora Cellars is the 25th winery along the trail. ... popular wine tour events, making its trail event debut during ... , Owners David and Faye Mathia opened the boutique ...
(Date:7/31/2014)... Ce-Classes.com has announced that they are now offering a ... Systematic Review of Sexual Satisfaction . The course ... of Clinical and Health Psychology. , This CE course ... have accurate information about sexual satisfaction so that healthcare ... material provides a systematic review of 197 research publications ...
(Date:7/31/2014)... In today’s world, a good night’s sleep ... and sleep apnea (a medical problem where the airway collapses ... partners of the rest they need to face their daily ... and 20 million people in the United States alone have ... treated; and of those treated, many cannot tolerate their prescribed ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 The vineyards are ... the upcoming harvest. And, to celebrate, folks are gearing up ... Sunday, September 6 and 7, 2014 along the Leelanau ... an optional walk or run through the vineyards start-ing at ... Suttons Bay. A unique course between rows of grapevines offers ...
(Date:7/31/2014)... Dayton, Ohio (PRWEB) July 31, 2014 ... members of its faculty, Anthony Le Donne and Peter ... 1. Also new to United is a Director ... on August 1. , Anthony Le Donne, Assistant ... University, United Kingdom. He teaches New Testament, Second Temple ...
Breaking Medicine News(10 mins):Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2Health News:Growing Seminary Welcomes New Faculty 2
... Upheld Against Mesothelioma Victim,s Former Employers, BATON ... after,winning a $3.2 million verdict against contractors Parsons ... on behalf of,mesothelioma victim Ray Rando, Baron & ... by the Louisiana First Circuit Court of Appeal.,Rando, ...
... studies in 15 Finnish families have shown that ... aptitude. Musical aptitude was determined using three tests: ... test), and the Seashore pitch and time discrimination ... genetic study that aims in the identification of ...
... (NEWARK, N.J., May 19, 2008) The New Jersey Department ... Governors Nursing Merit Award for excellence in the nurse researcher: ... faculty member, during a dinner at the Hyatt Regency Hotel, ... College of Nursing at Rutgers, The State University of New ...
... May 18, 2008 New study results indicated ... lead to significant relief of overall symptoms of Irritable ... presented at Digestive Disease Week (DDW) 2008, the largest ... , IBS-C is a multi-symptom disorder and is one ...
... The following is being,issued by AIDS Action:, ... Epidemic at Home: The Need for a National AIDS,Strategy", ... (Lunch provided at 12:45 p.m.), WHERE: Rayburn Building, ... Baldwin (D-WI), Representative Donna Christensen (D-VI), Representative ...
... Wi-Fi-Based Location Tracking Application to More than 50 ... ... Ekahau Inc., a leading,provider of Wi-Fi-based Real Time Location Systems (RTLS), ... organization in that country to use Ekahau RTLS to ensure the,safety of ...
Cached Medicine News:Health News:Asbestos Verdict Upheld by Louisiana Court of Appeal, Announces Baron & Budd 2Health News:Rutgers College of Nursing's Linda Flynn to receive N.J. Governor's Nursing Merit Award 2Health News:New AMITIZA 8 mcg phase III studies demonstrated overall symptom improvement in adult women 2Health News:Tuesday Congressional Briefing Relays Need for National AIDS Strategy 2Health News:Tuesday Congressional Briefing Relays Need for National AIDS Strategy 3Health News:GGZ-NML Hospital Deploys Ekahau RTLS for Staff Safety in Psychiatric Care Unit 2
For the quantitative in vitro determination of Digoxin in human serum....
For the quantitative in vitro determination of Microalbumin in urine....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Medicine Products: